Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour

British Journal of Nutrition

Volumn 102, Issue 3, 2009, Pages 434-442

  Xue, Hongyu ^a   Le Roy, Séverine ^b   Sawyer, Michael B ^a   Field, Catherine J ^a   Dieleman, Levinus A ^a   Baracos, Vickie E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

5 Fluorouracil; CPT 11; Glutamine; N 3 PUFA

Indexed keywords

FLUOROURACIL; GLUTAMINE; IRINOTECAN; OMEGA 3 FATTY ACID; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; LEUKOCYTE COUNT; LYMPHOCYTE; MONOTHERAPY; MUSCLE ATROPHY; MUSCLE MASS; NEUTROPHIL; NONHUMAN; NUTRITIONAL STATUS; RAT; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; COLON TUMOR; COMPARATIVE STUDY; DIARRHEA; DRUG SCREENING; FISCHER 344 RAT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; TREATMENT FAILURE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; CAMPTOTHECIN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIARRHEA; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FLUOROURACIL; GLUTAMINE; IMMUNE TOLERANCE; LEUKOCYTE COUNT; NUTRITIONAL STATUS; RATS; RATS, INBRED F344; TREATMENT FAILURE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70149111922     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114508199482     Document Type: Article

References (66)

1. Hardman WE (2002) Omega-3 fatty acids to augment cancer therapy. J Nutr 132, 3508S-3512S.
2. Savarese DM, Savy G, Vahdat L, et al. (2003) Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29, 501-513.
3. Xue H, Sawyer MB, Field CJ, et al. (2007) Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin Cancer Res 13, 7146-7154.
4. Ziegler TR (2002) Glutamine supplementation in bone marrow transplantation. Br J Nutr 87, Suppl. 1, S9-S15.
5. Baracos V, Mazurak V & Ma D (2004) n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev 17, 1-17.
6. Conklin KA (2002) Dietary polyunsaturated fatty acids: impact on cancer chemotherapy and radiation. Altern Med Rev 7, 4-21.
7. Grimble RF (2001) Nutritional modulation of immune function. Proc Nutr Soc 60, 389-397.
8. Choudhry MA, Haque F, Khan M, et al. (2003) Enteral nutritional supplementation prevents mesenteric lymph node T-cell suppression in burn injury. Crit Care Med 31, 1764-1770.
9. Chuntrasakul C, Siltham S, Sarasombath S, et al. (2003) Comparison of an immunonutrition formula enriched arginine, glutamine and omega-3 fatty acid, with a currently high-enriched enteral nutrition for trauma patients. J Med Assoc Thai 86, 552-561.
10. Pearce CB, Sadek SA, Walters AM, et al. (2006) A double-blind, randomised, controlled trial to study the effects of an enteral feed supplemented with glutamine, arginine, and omega-3 fatty acid in predicted acute severe pancreatitis. Jop 7, 361-371.
11. Yoshida S, Matsui M, Shirouzu Y, et al. (1998) Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Ann Surg 227, 485-491.
12. Garrel D (2004) The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns. JPEN J Parenter Enteral Nutr 28, 123, author reply 123.
13. Lai YN, Yeh SL, Lin MT, et al. (2004) Glutamine supplementation enhances mucosal immunity in rats with gut-derived sepsis. Nutrition 20, 286-291.
14. Roy N, Barnett M, Knoch B, et al. (2007) Nutrigenomics applied to an animal model of Inflammatory Bowel Diseases: transcriptomic analysis of the effects of eicosapentaenoic acid- and arachidonic acid-enriched diets. Mutat Res 622, 103-116.
15. Lin MT, Hsu CS, Yeh SL, et al. (2007) Effects of omega-3 fatty acids on leukocyte Th1/Th2 cytokine and integrin expression in rats with gut-derived sepsis. Nutrition 23, 179-186.
16. Hsu CS, Chiu WC, Yeh CL, et al. (2006) Dietary fish oil enhances adhesion molecule and interleukin-6 expression in mice with polymicrobial sepsis. Br J Nutr 96, 854-860.
17. Roth E & Kudsk KA (2004) Immunonutrition: back to science. JPEN J Parenter Enteral Nutr 28, 278, author reply 279-280.
18. Xue H, Sawyer MB, Field CJ, et al. (2008) Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr 138, 740-746.
19. Hwang PM, Bunz F, Yu J, et al. (2001) Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 7, 1111-1117.
20. Yanez JA, Teng XW, Roupe KA, et al. (2003) Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase-2. J Pharm Pharm Sci 6, 308-314.
21. Sadzuka Y & Hirota S (1997) Effect of CPT-11 on lipid peroxide level in mouse tissues. Jpn J Cancer Res 88, 512-516.
22. Timur M, Akbas SH & Ozben T (2005) The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line. Acta Biochim Pol 52, 897-902. (Pubitemid 43155020)
23. Wessner B, Strasser EM, Koitz N, et al. (2007) Green tea polyphenol administration partly ameliorates chemotherapy-induced side effects in the small intestine of mice. J Nutr 137, 634-640.
24. Cao S & Rustum YM (2000) Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60, 3717-3721.
25. Le Bricon T, Gugins S, Cynober L, et al. (1995) Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism 44, 1340-1348.
26. Melichar B, Touskova M, Solichova D, et al. (2001) CD4+Tlymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Invest 61, 363-370.
27. Johnson RA & Roodman GD (1989) Hematologic manifestations of malignancy. Dis Mon 35, 721-768.
28. Melichar B, TouskovaM&Vesely P (2002) Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer. Hepatogastroenterology 49, 967-970.
29. Tabuchi T, Ubukata H, Saniabadi AR, et al. (1999) Granulocyte apheresis as a possible new approach in cancer therapy: a pilot study involving two cases. Cancer Detect Prev 23, 417-421.
30. Zaloudik J, Lauerova L, Janakova L, et al. (1999) Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepatogastroenterology 46, 220-227.
31. Hannisdal E & Engan T (1991) Blood analyses and survival in symptom- and survey-detected lung cancer patients. J Intern Med 229, 337-341.
32. Harris J, Sengar D, Stewart T, et al. (1976) The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 37, 1058-1069.
33. Stock W & Hoffman R (2000) White blood cells 1: non-malignant disorders. Lancet 355, 1351-1357.
34. Ramos EJ, Middleton FA, Laviano A, et al. (2004) Effects of omega-3 fatty acid supplementation on tumor-bearing rats. J Am Coll Surg 199, 716-723.
35. Roynette CE, Calder PC, Dupertuis YM, et al. (2004) n-3 polyunsaturated fatty acids and colon cancer prevention. Clin Nutr 23, 139-151.
36. Knox WE, Horowitz ML & Friedell GH (1969) The proportionality of glutaminase content to growth rate and morphology of rat neoplasms. Cancer Res 29, 669-680.
37. Kovacevic Z & McGivan JD (1983) Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol Rev 63, 547-605.
38. Ollenschlager G, Simmel A & Roth E (1989) Availability of glutamine from peptides and acetylglutamine for human tumor-cell cultures. Metabolism 38, 40-42.
39. Knox WE, Linder M & Friedell GH (1970) A series of transplantable rat mammary tumors with graded differentiation, growth rate, and glutaminase content. Cancer Res 30, 283-287.
40. Moyer GH & Pitot HC (1974) Static and dynamic aspects of amino acid pools in rat liver and Morris hepatomas 9618A and 7800. Cancer Res 34, 2647-2653.
41. Austgen TR, Dudrick PS, Sitren H, et al. (1992) The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues. Ann Surg 215, 107-113.
42. Yoshida S, Kaibara A, Yamasaki K, et al. (1995) Effect of glutamine supplementation on protein metabolism and glutathione in tumor-bearing rats. JPEN J Parenter Enteral Nutr 19, 492-497.
43. Wang WS, Lin JK, Lin TC, et al. (2007) Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 12, 312-319.
44. Kaufmann Y, Kornbluth J, Feng Z, et al. (2003) Effect of glutamine on the initiation and promotion phases of DMBAinduced mammary tumor development. JPEN J Parenter Enteral Nutr 27, 411-418.
45. Fahr MJ, Kornbluth J, Blossom S, et al. (1994) Harry M. Vars Research Award. Glutamine enhances immunoregulation of tumor growth. JPEN J Parenter Enteral Nutr 18, 471-476.
46. Klimberg VS, Kornbluth J, Cao Y, et al. (1996) Glutamine suppresses PGE2 synthesis and breast cancer growth. J Surg Res 63, 293-297.
47. TodorovaVK, Harms SA, Kaufmann Y, et al. (2004) Effect of dietary glutamine on tumor glutathione levels and apoptosis-related proteins in DMBA-induced breast cancer of rats. Breast Cancer Res Treat 88, 247-256.
48. Pardini RS (2006) Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. Chem Biol Interact 162, 89-105.
49. Rubio IT, Cao Y, Hutchins LF, et al. (1998) Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg 227, 772-778, discussion 778-780.
50. Balendiran GK, Dabur R & Fraser D (2004) The role of glutathione in cancer. Cell Biochem Funct 22, 343-352.
51. Germain E, Chajes V, Cognault S, et al. (1998) Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75, 578-583.
52. Rouse K, Nwokedi E, Woodliff JE, et al. (1995) Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 221, 420-426.
53. Hardman WE, Avula CP, Fernandes G, et al. (2001) Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 7, 2041-2049.
54. Hardman WE, Moyer MP & Cameron IL (2002) Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 86, 983-988.
55. Khan SA & Wingard JR (2001) Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 29, 31-36.
56. Hoensch H, Morgenstern I, Petereit G, et al. (2002) Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. Gut 50, 235-240.
57. Barbosa DS, Cecchini R, El Kadri MZ, et al. (2003) Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 19, 837-842.
58. Camuesco D, Galvez J, Nieto A, et al. (2005) Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr 135, 687-694.
59. Simopoulos AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21, 495-505.
60. Calder PC (2003) n-3 Polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38, 343-352.
61. Pavlick KP, Laroux FS, Fuseler J, et al. (2002) Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33, 311-322.
62. Exner R, Tamandl D, Goetzinger P, et al. (2003) Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide- stimulated tumor necrosis factor-alpha response. Ann Surg 237, 110-115.
63. Gennari R, Alexander JW & Eaves-Pyles T (1995) Effect of different combinations of dietary additives on bacterial translocation and survival in gut-derived sepsis. JPEN J Parenter Enteral Nutr 19, 319-325.
64. Wessner B, Strasser EM, Spittler A, et al. (2003) Effect of single and combined supply of glutamine, glycine, N-acetylcysteine, and R,S-alpha-lipoic acid on glutathione content of myelomonocytic cells. Clin Nutr 22, 515-522.
65. Hamani D, Charrueau C, Butel MJ, et al. (2007) Effect of an immune-enhancing diet on lymphocyte in head-injured rats: what is the role of arginine? Intensive Care Med 33, 1076-1084.
66. Boelens PG, Melis GC, Van Leeuwen PA, et al. (2006) Route of administration (enteral or parenteral) affects the contribution of L-glutamine to de novo L-arginine synthesis in mice: a stable-isotope study. Am J Physiol Endocrinol Metab 291, E683-E690.